GondolaBio is a clinical-stage biopharmaceutical company focused on developing next-generation therapeutics for genetic diseases. Originally launched as BridgeBioX, a subsidiary of BridgeBio, GondolaBio secured $300M in private financing from external investors in 2024 and became an independent company within the BridgeBio ecosystem. The company aims to leverage cutting-edge biological research to create breakthrough medicines addressing high unmet needs across multiple therapeutic areas, including neurology, pulmonology, cardiology, nephrology, and endocrinology. Located on the Stanford Life Sciences campus, GondolaBio fosters a unique hybrid environment where top scientists from around the world collaborate with senior leadership and advisors, blending industry expertise with academic innovation.

Biotechnology

Health Care

Life Sciences

Therapeutics

GondolaBio

GondolaBio's headquarters in Palo Alto, United States

This department focuses on the strategies and processes that drive business development and operational efficiency.

Business Development Operations

This department focuses on scientific research and innovation to advance product development and improve outcomes.

Research and Development

This department focuses on bridging laboratory research and clinical applications to advance medical treatments.

Translational Biology

This department focuses on acquiring and managing academic partnerships and talent to support organizational goals.

Asset Acquisition

This department focuses on identifying growth opportunities and managing operational strategies to enhance the organization's market presence.

Business Development

This department oversees the research and development processes for new pharmaceuticals.

��

People (8)

Jobs (0)

Other teams

Research and Development

Translational Biology

Asset Acquisition

Business Development

Drug Development

��������

People (8)

Jobs (0)

Other teams

Research and Development

Translational Biology

Asset Acquisition

Business Development

Drug Development

��